



MODERN SLAVERY TRANSPARENCY STATEMENT

This statement is published by LGC Science Group Holdings Limited and its relevant subsidiaries¹ pursuant to: (i) Section 54(1) of the Modern Slavery Act 2015 (the “Act”) and (ii) California Transparency in Supply Chains Act 2010 (SB657) (the “CTSCA”) for the financial year ending 31 March 2019.

Statements for years 2016, 2017 and 2018 respectively can be viewed at www.lgcgroup.com

1. Introduction

“Science for a safer world” is integral to how we operate and informs how we conduct business at LGC. We are committed to the continuous improvement of our business practices and how we view our operations and wider supply chain. This includes assessing and minimising risk arising from slavery, servitude, forced and compulsory labour and human trafficking (collectively “modern slavery”).

2. Our business

LGC is a leading international life sciences tools business providing products and services to customers in a wide range of markets. We provide a comprehensive range of reference materials, proficiency testing schemes, genomics reagents and instrumentation, as well as research and measurement services. We work with customers in the pharmaceuticals, agricultural, biotechnology, food, environment, security and sports sectors, as well as with governments and academia.

LGC is headquartered in Greater London, operates out of 19 countries and employs more than 2700 people worldwide. Our origins can be traced back to 1842 when the Laboratory of the Board of Excise was founded. We are the UK National Measurement Laboratory and Designated Institute for chemical and bio-measurement and have been home to the UK’s Laboratory of the Government Chemist for more than 100 years. LGC is now owned by funds affiliated with KKR.

3. Our policies and practices

At LGC, “integrity” and “respect” are two of our core values. Many of our policies reflect our commitment to act with integrity and respect in all our business interactions and therefore minimise the risk of modern slavery in our business and wider supply chain. These include LGC’s Code of Ethics and underpinning policies on: Equality & Diversity; Resourcing; Employing Overseas Nationals; as well as processes for supplier selection and diligence. LGC personnel are accountable for compliance with company policies and procedures which includes a requirement to ensure LGC operates in compliance with the law.

LGC’s Supplier Code of Conduct imposes specific obligations on suppliers to not engage in modern slavery of any kind. LGC expects to work with suppliers that adhere to our core values in all business transactions and all suppliers are required to commit to the Supplier Code of Conduct as a condition of doing business with LGC. All suppliers are contractually obliged to communicate their obligations within the Supplier Code of Conduct to their employees and subcontractors.

¹LGC Limited and LGC Genomics Limited are the relevant subsidiaries pursuant to the Act and Biosearch Technologies Inc. is the relevant subsidiary in respect of the CTSCA.

LGC continues to operate a Whistleblowing procedure, allowing employees to report concerns about the actions of suppliers, managers and other employees anonymously and in confidence. This includes concerns of corruption, unethical or illegal action or human rights infractions. All reports are assessed to determine the scope and need for an investigation.

4. Risk assessment and due diligence

LGC's risk assessment processes indicate that across our businesses the risk associated with modern slavery including our wider supply chain continues to be low. LGC is a global business and has a global supply chain. As a consequence of the highly specialised nature of our businesses, the vast majority of LGC's suppliers are located in low risk sectors and geographies and LGC typically seeks to engage with strategic suppliers only. Our suppliers are predominantly based in the UK, EU, United States of America and Australia. As part of LGC's initiative to identify and mitigate risk, we conduct due diligence, including financial checks on all new suppliers, contractors, sub-contractors, distributors, agents and customers. These checks help identify and verify that such parties are not involved with, or suspected of, modern slavery, bribery, corruption or other unlawful activity. We are planning to introduce new resources in respect of counterparty checking in the next 12 months. Our commitment to continuous improvement can be seen through the Supplier Code of Conduct, which sets out further standards which LGC expects its suppliers to adhere to and provides reassurance to LGC on its supplier's compliance policies and procedures in addition to those relating to modern slavery.

Following a review of LGC's supplier on-boarding processes over the last year, LGC's standard terms of procurement now expressly require suppliers to comply with the LGC Supplier Code of Conduct along with requiring suppliers to comply with all applicable laws in the provision of products and services to LGC. We typically reserve the right to conduct supplier audits to underpin these requirements.

5. Training

LGC continues to periodically deliver training on counterparty checking of both customers and suppliers to LGC personnel in a systematic and targeted manner, as informed by LGC's risk assessment processes. In May 2019, we launched new compulsory anti-bribery and corruption training to all employees. We continue to review the compliance training offered to employees to ensure compliance with applicable laws, including those in connection with modern slavery.

6. Next steps

LGC is not aware of any established instance of modern slavery in our business or wider supply chain. As our business continues to grow, we remain committed to integrating our businesses with uniform policies and procedures which highlight and educate our personnel and suppliers of the risk of modern slavery. As such, identification and management of modern slavery risk will continue to inform the update of LGC's compliance processes and policies.

This statement has been approved by the Board of each of LGC Science Group Holdings Limited, LGC Limited and LGC Genomics Limited in compliance with the Act and by the Board of Biosearch Technologies Inc. in connection with the CTSCA. It was approved by the Board of LGC Science Group Holdings Limited on 26 June 2019.

T M Robinson
Chief Executive Officer of LGC
26 June 2019